Previous 10 | Next 10 |
2023-04-11 10:05:56 ET Fulgent Genetics ( NASDAQ: FLGT ) and Mission Bio are collaborating to broaden accessibility of single-cell multi-omics for drug development and clinical research. Fulgent said it is now able to offer single-cell multi-omics on the Tapestri Platform...
Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research PR Newswire Strategic partnership between Mission Bio and Fulgent Genetics will enable drug developers to leverage single-cell multi-omics ...
Fulgent Genetics, Inc. (FLGT) Q4 2022 Earnings Conference Call February 28, 2023 16:30 ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer ...
Fulgent Genetics press release ( NASDAQ: FLGT ): Q4 Non-GAAP EPS of -$0.48 beats by $0.08 . Revenue of $67.7M (-73.1% Y/Y) beats by $8.13M . Core Revenue grew 97% year-over-year to $55.0 million For the first quarter of 2023, Fulgent expects: Total Reve...
Full Year 2022 Total Revenue of $619.0 million; Q4 Total Revenue of $67.7 million Full Year 2022 Core Revenue grows 95% year-over-year to $181.5 million; Q4 Core Revenue grows 97% year-over-year to $55.0 million Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the ...
New 787 gene panel becomes the largest panel available on Fulgent Genetics’ platform, setting a new standard for patients seeking the most comprehensive option for carrier screening Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a ...
Fulgent Genetics ( NASDAQ: FLGT ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, after market close. The consensus EPS Estimate is -$0.56 (vs. $3.48 last year) and the consensus Revenue Estimate is $59.57M (-76.3% Y/Y). Over the last 2 years, FLGT ha...
Fulgent, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Ra...
Summary Today, we revisit Fulgent Genetics. The company continues to manage through a huge drop off in Covid testing revenues as the pandemic ebbs. However, 'core' testing sales are seeing impressive growth and the company has a massive amount of cash on its balance sheet. An u...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it w...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...